Puma Biotechnology, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022; filed March 2, 2023. This 10-K reports annual results. The filing text does not provide a clear standalone Q4 financial breakdown.
Business context
Puma is a biopharmaceutical company primarily dependent on NERLYNX (neratinib), its only marketed product, approved in the United States for certain early-stage and metastatic HER2-positive breast cancers. It sells through a U.S. specialty sales force and relies on sublicensees outside the United States. In September 2022, Puma licensed worldwide rights to investigational alisertib from Takeda and assumed global development and commercialization responsibilities.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Total revenue | $228.0 million | $253.2 million |
| Product revenue, net | $200.0 million | $189.1 million |
| License revenue | $0 | $51.8 million |
| Royalty revenue | $28.0 million | $12.3 million |
| Operating income | $23.7 million | $1.3 million |
| Net income (loss) | $0.002 million | $(29.1) million |
| Cash from (used in) operating activities | $(15.8) million | $20.7 million |
- Revenue declined about 9.9%, principally because FY2021 included a $51.8 million sublicense payment. Product revenue increased about 5.8%; higher net selling price and lower variable-consideration reserves more than offset a 4.6% decrease in bottles sold. Royalty revenue rose with sublicensee sales, including in China.
- Cost of sales was $55.1 million versus $63.7 million; FY2021 included a one-time $20.0 million CANbridge termination expense. Gross profit was approximately $172.9 million, or 75.8% of revenue, compared with approximately $189.5 million, or 74.8%, in FY2021 (calculated from reported revenue and cost of sales).
- SG&A fell 22.6% to $90.0 million, and R&D fell 27.3% to $52.2 million, reflecting lower personnel, stock compensation and clinical activity. FY2022 includes a $7.0 million alisertib in-process R&D charge.
- Cash and cash equivalents were $76.2 million and marketable securities $4.9 million at year-end, totaling approximately $81.1 million. Working capital was $56.8 million, compared with $30.4 million in 2021.
- Athyrium debt had $100.0 million principal outstanding ($98.3 million net carrying value), a 12.99% effective interest rate, and a July 2026 maturity. Interest is floating-rate; quarterly principal payments begin in June 2024. Puma reported compliance with covenants at year-end.
- Financing activities provided $12.2 million in FY2022, mainly from equity purchases; investing activities provided $7.1 million. Stockholders’ equity was $21.6 million, versus a $2.4 million deficit at year-end 2021.
Material changes, outlook and key risks
- Management said existing cash, marketable securities, product sales and sublicense proceeds were expected to fund operating and capital needs for at least one year after filing. It also expects significant expenses and possible operating losses as it commercializes NERLYNX and develops alisertib; continued funding and revenue growth remain important.
- Takeda received a $7.0 million upfront alisertib payment. The agreement provides for up to $287.3 million in potential regulatory and commercial milestones, plus tiered royalties. Puma planned to discuss the development plan and dosing with the FDA in the first half of 2023; these were plans, not assured outcomes.
- NERLYNX sales remain concentrated: two customers represented approximately 35% and 20% of FY2022 product revenue. The company also depends on third-party manufacturers and foreign sublicensees.
- NERLYNX-associated diarrhea is a material tolerability issue. The CONTROL study found the lowest grade 3 diarrhea incidence in its dose-escalation 1 cohort (13%); Puma submitted study results to health authorities to support labeling changes.
- Cash generated by operations weakened to a $15.8 million outflow. Management cited working-capital movements, including a $33.1 million decrease in accrued expenses, and higher receivables as factors.
- Significant litigation cash costs and accruals: Puma paid approximately $54.2 million to resolve the Hsu matter in 2022. It agreed to a $16.0 million Eshelman settlement; $8.0 million was paid in January 2023 and the remaining $8.0 million is due by November 1, 2024. A related malpractice claim was dismissed without prejudice, with potential recovery uncertain.
- Generic competition and patent disputes warrant monitoring. Puma settled U.S. Sandoz litigation, allowing potential generic neratinib sales around December 2030, subject to agreement terms. Chinese generic applications and related patent proceedings remained active.
- Other risks include debt covenants requiring minimum revenue and cash balances, pricing and reimbursement pressures, the Inflation Reduction Act, clinical-development uncertainty, competition, and potential financing needs. The company reported no off-balance-sheet arrangements.
- KPMG issued an unqualified opinion on the financial statements and internal controls. The auditor identified estimates for product-revenue variable consideration, particularly provider chargebacks and government rebates, as a critical audit matter.
Most important facts for investors to verify
- Whether NERLYNX product sales and sublicense royalties can sustain revenue as the FY2021 license-payment comparison drops out, and whether customer concentration changes.
- Cash burn, working-capital trends, covenant headroom, the 12.99% debt cost and the timing of principal repayments.
- Actual alisertib development costs, FDA feedback, trial design and financing capacity relative to its potential milestone obligations.
- Updates to NERLYNX generic entry timing, Chinese patent challenges, and any effect on sales, exclusivity or royalties.
- Settlement payments and any developments in the malpractice action, as well as the assumptions behind revenue reserves and other legal accruals.